Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anesiva has said the FDA has granted orphan drug status to its product candidate 4975 for the treatment of a painful foot condition known as interdigital neuroma in patients who fail traditional treatments.
Subscribe to our email newsletter
Patients administered 4975 have not responded to the current treatments such as such as foot pads, non-steroidal anti-inflammatory drugs and injections of corticosteroids and would otherwise had the nerve causing the pain removed.
The standard treatments for interdigital neuroma fail in approximately 50% of patients.
Orphan drug designation is granted by the FDA to encourage companies to develop products that treat rare diseases and conditions. The status has benefits which include market exclusivity for seven years, tax credits on qualified clinical trial expenses and a waiver of the FDA prescription drug user fees.
Data from a phase II clinical trial in patients with interdigital neuroma demonstrated that 4975 produced a statistically significant reduction in foot pain for four weeks following a single injection when compared to placebo treatment.
In clinical studies to date, 4975 has not had the side effects often associated with other conventional pain medications and has been shown to be well tolerated.